longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Neumora Therapeutics

NMRA

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Weekly Recap | Zai Lab -2.8%, most brokers rate it buy

    Weekly Review·2 days ago, 07:23 AM
    - Zai Lab shares fell 2.8% to close at 24.98 USD this week, underperforming the S&P 500 index by 4.01 percentage points amid shrinking trading volume and no major catalysts. - Among 12 covering institutions, 9 rated the stock as a buy and 2 as overweight, resulting in a strong buy consensus with an average target price of 33.14 USD. - Next week's focus will center on US macroeconomic data impacting the biotechnology sector's risk appetite, while Zai Lab has no major events or earnings reports scheduled.
    ZLAB+2.84%
  • Weekly Recap | Sarepta Therap -7.16%, consensus target above spot

    Weekly Review·2 days ago, 07:08 AM
    SRPT+0.70%SRPU0.00%
  • Weekly Recap | Novavax +5.14%, consensus target above spot

    Weekly Review·2 days ago, 06:55 AM
    NVAX+1.60%
  • Weekly Recap | Legend Biotech +8.52%, most brokers rate it buy

    Weekly Review·2 days ago, 06:37 AM
    LEGN-2.56%
  • Weekly Recap | IOVA.US +7.32%, most brokers rate it buy

    Weekly Review·2 days ago, 06:33 AM
    IOVA-0.09%
  • Weekly Recap | GENB.US -11.61%, consensus target above spot

    Weekly Review·2 days ago, 06:23 AM
    GENB-1.58%
  • Weekly Recap | Cypherpunk Tech +14.44%, a sharp V-shaped recovery

    Weekly Review·2 days ago, 06:13 AM
    CYPH-19.66%
  • Weekly Recap | CRISPR Therap -4.12%, most brokers rate it buy

    Weekly Review·2 days ago, 06:12 AM
    CRSP-0.26%
  • The Nasdaq Biotechnology Index fell by more than 1.2%. Among them, Medpace dropped 15.90%, Tectonic Therapeutic fell 15.22%, Regenxbio decreased 14.31%, Humacyte declined 13.93%, and Anavex Life Sciences fell 8.74%. In contrast, Mesoblast rose 7.21%, Personalis increased 10.03%, Invivyd gained 10.14%, PepGen surged 17.99%, and Neumora Therapeutics jumped 25.10%

    Wallstreetcn·Feb 10 at 11:10 PM
    IDNA+0.05%RGNX+0.95%
  • OpenAI's CEO Altman: The company may seek partners or invest in AI drug discovery

    Wallstreetcn·Feb 3 at 05:45 PM
    520500+1.98%159992-0.71%
  • The Nasdaq Biotechnology Index fell by more than 2%. Among them, Sutro Biopharma dropped 12.98%, Kyverna Therapeutics fell 10.95%, GRAIL decreased 10.01%, and Pyxis Oncology declined 9.34%. Ironwood Pharma rose 4.44%, Arrowhead Pharmaceuticals increased 4.63%, Neumora Therapeutics grew 6.92%, and Q32 Bio surged 92.69%

    Wallstreetcn·Dec 1, 2025 at 05:39 PM
    IRWD-0.24%STRO+0.31%